Cancer
7 competing products in clinical development for Cancer.
Pipeline by Phase
Phase 13
Phase 1/21
Phase 23
All Products (7)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Veliparib | AbbVie | Phase 2 | Withdrawn | 52 |
| Bevacizumab + Cetuximab + Pemetrexed | Eli Lilly | Phase 2 | Completed | 52 |
| Fludarabine (Conditional therapy) + Cyclophosphamide Monohydrate (Conditional therapy) + firi-cel (Experimental drug) | CARGO Therapeutics | Phase 2 | Terminated | 44 |
| E7389 | Eisai | Phase 1 | Completed | 33 |
| LY3300054 + Prexasertib | Eli Lilly | Phase 1 | Completed | 33 |
| eFT508 | eFFECTOR Therapeutics | Phase 1/2 | Terminated | 33 |
| XL820 | Exelixis | Phase 1 | Completed | 30 |